Monotherapy for Rheumatoid Arthritis: Leveraging the Latest Evidence to Treat to Target

In this interactive, CME/CE/CPE-certified video module, Jonathan Scott Coblyn, MD; Jessica Farrell, PharmD; and Frances Griffin, RN, BSN, provide multidisciplinary perspectives on best practices in the use of traditional, biologic, and targeted synthetic DMARD monotherapy to treat rheumatoid arthritis.

Jonathan Scott Coblyn, MD
Program Director Jessica Farrell, PharmD Frances Griffin, RN, BSN Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 29, 2018 Expired: No longer available for credit

In this downloadable slideset, Jonathan Scott Coblyn, MD; Jessica Farrell, PharmD; and Frances Griffin, RN, BSN, provide an overview of best practices in the use of monotherapy to treat rheumatoid arthritis.

Jonathan Scott Coblyn, MD
Program Director Jessica Farrell, PharmD Frances Griffin, RN, BSN Released: June 29, 2018

Here’s my take on the patients who are best suited to receive biologic or targeted synthetic DMARD monotherapy.

Roy Fleischmann, MD Released: June 8, 2018

What are the data supporting the use of newer agents as monotherapy for patients with RA? Here’s my take.

Jasvinder Singh, MD, MPH Released: August 2, 2018